Literature DB >> 29520587

P-glycoprotein Restricts Ocular Penetration of Loperamide across the Blood-Ocular Barriers: a Comparative Study in Mdr1a Knock-out and Wild Type Sprague Dawley Rats.

Akshaya Tatke1, Karthik Yadav Janga1, Bharathi Avula2, XiangDi Wang3, Monica M Jablonski3, Ikhlas A Khan2, Soumyajit Majumdar4.   

Abstract

The current research was undertaken to determine the existence and magnitude of P-glycoprotein (P-gp) expression on the blood-ocular barriers by studying the ocular penetration of loperamide, a specific P-gp substrate, in P-gp (Mdr1a) knock-out (KO) and wild type (WT) Sprague Dawley rats. A clear, stable, sterile solution of loperamide (1 mg/mL), for intravenous administration, was formulated and evaluated. Ocular distribution was studied in P-gp KO and WT rats following intravenous administration of loperamide (at two doses). The drug levels in plasma, aqueous humor (AH), and vitreous humor (VH) samples were determined with the aid of UHPLC-Q-TOF-MS/MS, and the AH/plasma (D AH ) and VH/plasma (D VH ) distribution ratios were estimated. Electroretinography (ERG), ultrastructural analyses, and histology studies were carried out, in both KO and WT rats, to detect any drug-induced functional and/or structural alterations in the retina. Dose-related loperamide levels were observed in the plasma of both WT and KO rats. The loperamide concentrations in the AH and VH of KO rats were significantly higher compared to that observed in the WT rats, at the lower dose. However, a marked increase in the D AH and D VH was noted in the KO rats. ERG, ultrastructure, and histology studies did not indicate any drug-induced toxic effects in the retina under the test conditions. The results from these studies demonstrate that P-gp blocks the penetration of loperamide into the ocular tissues from the systemic circulation and that the effect is more pronounced at lower plasma loperamide concentrations.

Entities:  

Keywords:  P-glycoprotein; blood-ocular barriers; electroretinography; ocular distribution; retinal pigmented epithelium

Mesh:

Substances:

Year:  2018        PMID: 29520587      PMCID: PMC7325844          DOI: 10.1208/s12249-018-0979-2

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  40 in total

Review 1.  The blood-retinal barriers system. Basic concepts and clinical evaluation.

Authors:  José G Cunha-Vaz
Journal:  Exp Eye Res       Date:  2004-03       Impact factor: 3.467

2.  Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.

Authors:  Chetan S Karyekar; Natalie D Eddington; Tushar S Garimella; Paul O Gubbins; Thomas C Dowling
Journal:  Pharmacotherapy       Date:  2003-04       Impact factor: 4.705

3.  Stimulation of μ-opioid receptors dilates retinal arterioles by neuronal nitric oxide synthase-derived nitric oxide in rats.

Authors:  Eriko Someya; Asami Mori; Kenji Sakamoto; Kunio Ishii; Tsutomu Nakahara
Journal:  Eur J Pharmacol       Date:  2017-03-22       Impact factor: 4.432

4.  Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor.

Authors:  J V Aukunuru; G Sunkara; N Bandi; W B Thoreson; U B Kompella
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

5.  P-glycoprotein expression in human retinal pigment epithelium.

Authors:  Brian G Kennedy; Nancy J Mangini
Journal:  Mol Vis       Date:  2002-11-11       Impact factor: 2.367

Review 6.  Advances in the cell biology of transport via the inner blood-retinal barrier: establishment of cell lines and transport functions.

Authors:  Ken-ichi Hosoya; Masatoshi Tomi
Journal:  Biol Pharm Bull       Date:  2005-01       Impact factor: 2.233

Review 7.  Dry age-related macular degeneration: recent progress of therapeutic approaches.

Authors:  Noriyuki Kuno; Shinobu Fujii
Journal:  Curr Mol Pharmacol       Date:  2011-11       Impact factor: 3.339

8.  Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.

Authors:  Soumyajit Majumdar; Ketan Hippalgaonkar; Ramesh Srirangam
Journal:  Drug Metab Dispos       Date:  2009-04-30       Impact factor: 3.922

9.  Elovl4 5-bp deletion knock-in mouse model for Stargardt-like macular degeneration demonstrates accumulation of ELOVL4 and lipofuscin.

Authors:  Vidyullatha Vasireddy; Monica M Jablonski; Naheed W Khan; Xiao Fei Wang; Priya Sahu; Janet R Sparrow; Radha Ayyagari
Journal:  Exp Eye Res       Date:  2009-08-13       Impact factor: 3.467

10.  Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics.

Authors:  Maciej J Zamek-Gliszczynski; Keith M Goldstein; April Paulman; Thomas K Baker; Timothy P Ryan
Journal:  Drug Metab Dispos       Date:  2013-04-08       Impact factor: 3.922

View more
  2 in total

1.  Retina Compatible Interactions and Effective Modulation of Blood Ocular Barrier P-gp Activity by Third-Generation Inhibitors Improve the Ocular Penetration of Loperamide.

Authors:  Karthik Yadav Janga; Akshaya Tatke; Surabhi Shukla; Surya P Lamichhane; Bharathi Avula; XiangDi Wang; Monica M Jablonski; Ikhlas A Khan; Soumyajit Majumdar
Journal:  J Pharm Sci       Date:  2018-04-17       Impact factor: 3.534

Review 2.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Authors:  Sandra D Comer; Catherine M Cahill
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.